Patients with OSA or high nocturnal arousal burden may require higher trazodone doses, but OSA is better treated as a covariate than a lead disease-modification hypothesis
OSA-related arousal burden could raise the dose needed for any sleep-mediated neuroprotective effect, perhaps toward 100 mg rather than 50 mg. This is the least supported development hypothesis because it depends on a long causal chain from OSA physiology to biomarker benefit in dementia and is heavily confounded by standard OSA care and endotype heterogeneity.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Obstructive Sleep Apnea Nocturnal Arousal Burden"]
B["HTR2A Signaling Serotonin Receptor 2A"]
C["HRH1 Histamine Receptor Mediator Release"]
D["Sleep Architecture Disruption"]
E["Higher Trazodone Dose Requirement"]
F["REM Suppression Sleep Quality Impact"]
G["Precision Dosing via HTR2A/HRH1 Stratification"]
A --> B
A --> C
B --> D
C --> D
D --> E
E --> F
G -.->|"optimizes"| E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Median TPM across 13 brain regions for HTR2A; HRH1 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations8 with PMIDValidation: 0%5 supporting / 3 opposing
✓For(5)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
1
1
MECH 6CLIN 0GENE 1EPID 1
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Trazodone 100 mg increased arousal threshold in OS…
Histamine H1 Receptors in Neural Stem Cells Are Required for the Promotion of Neurogenesis Conferred by H3 Rec…▼
Histamine H1 Receptors in Neural Stem Cells Are Required for the Promotion of Neurogenesis Conferred by H3 Receptor Antagonism following Traumatic Brain Injury.
Clemastine promotes recovery of neural function and suppresses neuronal apoptosis by restoring balance of pro-…▼
Clemastine promotes recovery of neural function and suppresses neuronal apoptosis by restoring balance of pro-inflammatory mediators in an experimental model of intracerebral hemorrhage.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for HTR2A; HRH1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF older adults with high nocturnal arousal burden (>15 arousals/hour on polysomnography) receive 100 mg trazodone versus 50 mg trazodone for 12 weeks, THEN the high-dose group will show superior improvement in sleep efficiency (≥8% absolute increase) and CSF neurofilament light chain levels will decline by ≥15% relative to low-dose group.
pendingconf: 0.25
Expected outcome: Sleep efficiency increases by ≥8% in high-dose group; CSF NfL decreases by ≥15% relative to low-dose group within 3 months
Falsified by: No significant difference in sleep efficiency between 50 mg and 100 mg doses (p > 0.05) OR CSF NfL levels increase or remain stable in high-dose arm
Method: Phase 2b randomized, double-blind, dose-finding trial enrolling 120 older adults (≥65 years) with mild cognitive impairment and insomnia, stratified by polysomnography-confirmed arousal index (high vs. low) and APOE4 status; trazodone vs. placebo arms at two dose levels with 12-week intervention
IF OSA status is added as a stratification variable to a cohort receiving trazodone 50 mg nightly for 8 weeks, THEN patients without OSA will exhibit significantly greater improvement in next-morning cognition (Digit Symbol Substitution Test) than patients with OSA, controlling for age, BMI, and baseline cognition.
pendingconf: 0.20
Expected outcome: Non-OSA group shows ≥20% greater improvement in DSST scores compared to OSA group at 8 weeks
Falsified by: No significant difference in cognitive improvement between OSA and non-OSA groups (p > 0.05) OR OSA patients show equal or greater DSST improvement compared to non-OSA patients
Method: Secondary analysis of a prospective cohort of 200 older adults (≥60 years) with suspected sleep fragmentation recruited from memory clinics; OSA status confirmed by overnight home sleep apnea testing (AHI ≥15); trazodone 50 mg nightly; DSST and polysomnography endpoints at baseline and 8 weeks
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
HTR2A; — Search for structure
Click to search RCSB PDB